Pcsk9
-
Official Full Name
proprotein convertase subtilisin/kexin type 9
-
Background
This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014] -
Synonyms
PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein;
- Involved Pathway
- Protein Function
- Interacting Protein
- Pcsk9 Related Articles
- Pcsk9 Related Research Area
Pcsk9 involved in several pathways and played different roles in them. We selected most pathways Pcsk9 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with Pcsk9 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|
Pcsk9 has several biochemical functions, for example, apolipoprotein binding, apolipoprotein receptor binding, low-density lipoprotein particle binding. Some of the functions are cooperated with other proteins, some of the functions could acted by Pcsk9 itself. We selected most functions Pcsk9 had, and list some proteins which have the same functions with Pcsk9. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| apolipoprotein binding | LRP4;LPA;ABCA1;VLDLR;PLG;LRP1;CANX;LRP6;MAPT |
| apolipoprotein receptor binding | APOA1;APOA2;PCSK9 |
| low-density lipoprotein particle binding | CDH13;PCSK9;SCARF1;MSR1;SORL1;SCARB1;LIPC;ANKRA2;LDLR |
| low-density lipoprotein particle receptor binding | ARRB2;DNAJA1;HSP90B1;PCSK9;AP2M1;MMP13;APOEA;CRP;CCDC167 |
| poly(A) RNA binding | ARF1;COA6;EIF4A3;ALG13;FYTTD1;WDR6;RPL3;DHX8;MRPL9 |
| protein binding | POLB;NUP85;A1CF;CYCS;FAM195A;CHCHD3;CCT6A;S100A16;TPSB2 |
| protein self-association | L1CAM;TP53;PCSK9;TMEM190;TTN;NKX3;MDH2;CCL5;SLC2A1 |
| receptor inhibitor activity | |
| serine-type endopeptidase activity | PCSK6;F9A;PROC;PCSK5;PROZ;PRSS28;KLK1B22;HGF;PRSS41 |
| sodium channel inhibitor activity | SLC14A2;SCN1B;CAMK2D;NEDD4L;PCSK9;NEDD4 |
| very-low-density lipoprotein particle binding | VLDLR;PCSK9 |
| very-low-density lipoprotein particle receptor binding | APOEA;APOEB;Reln;APOE;LRPAP1;PCSK9 |
Pcsk9 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with Pcsk9 here. Most of them are supplied by our site. Hope this information will be useful for your research of Pcsk9.
LDLR; MMP2; ANXA2
- Q&As
- Reviews
Q&As (6)
Ask a questionYes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Ask a Question for All Pcsk9 Products
Required fields are marked with *
My Review for All Pcsk9 Products
Required fields are marked with *